Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
Niharika B. Mettu(Duke Medical Center), Tanios Bekaii‐Saab(AstraZeneca (United Kingdom))
Cited by 121
Related Papers
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
|Journal of Clinical Oncology|2011|304